Table 2.

Assumptions on model variables, including costs of medication, disease status, treatment procedures, visits, and tests with additional assumptions on the prevalence and effectiveness of finasteride on benign prostate hypertrophy

VariableBase caseRange in sensitivity analysis
Medications (annual costs, U.S. dollars)
    Finasteride (19)749713-959
    Leuprolide acetate (11)5,7092,317-8,111
    α Blocker (19)432288-840
Disease states (annual costs, U.S. dollars)
    Biochemical recurrence (11)371231-927
    Metastasis (11)463231-927
Other (one-time cost, U.S. dollars)
    Cost of terminal care for prostate cancer (11-13)40,7446,714-47,601
    Radical retropubic prostatectomy (20)18,00015,675-21,020
    Complications from retropubic prostatectomy (20)2,4451,500-4,000
    Physician visit*6050-100
    PSA laboratory test*76-60
    Transurethral resection of prostate*4,597
Prevalence of benign prostatic hyperplasia (14)
    Age <65 y0.150.10-20
    Age ≥65 y0.220.14-30
Relative effect of finasteride on prevalence of benign prostatic hyperplasia, % (3)6050-100
Discount Rate, % (16, 17)31-5
  • * Local cost estimates.